Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results...

Related Keywords

United States ,American ,Carl Spana ,Palatin Technologies Inc ,Prnewswire Palatin Technologies Inc ,Securities Exchange ,Dry Eye Disease Ongoing ,Interim Analysis ,Study Size ,Product Revenue Increased ,Prescriptions Dispensed Increased ,Refills Exceed ,Total Prescriptions ,Ulcerative Colitis Commenced ,Interim Analysis First Quarter Calendar ,Currently Expected ,Third Quarter Calendar ,Registered Direct ,Fiscal First Quarter Ended September ,Hypoactive Sexual Desire Disorder ,Direct Offering ,Common Warrant ,Pre Funded Warrant ,Common Warrants ,Pre Funded Warrants ,Stock Split ,Common Stock ,First Quarter Ended September ,Registered Direct Offering ,Private Placement ,Redeemable Convertible Preferred ,Eastern Time ,Melanocortin Receptor Agonists ,Palatin Technologies ,Securities Exchange Act ,Private Securities ,Months Ended September ,Seriesc Redeemable Convertible Preferred Stock ,Nc ,Biotechnology ,Pharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Earnings ,